Quarterly ResultMay 12, 2026, 05:11 PM
BridgeBio Oncology Q1 2026 Results; Positive Clinical Data & Cash Runway
AI Summary
BridgeBio Oncology Therapeutics reported its first quarter 2026 financial results, alongside significant clinical progress across its three RAS-pathway inhibitor programs. The company announced encouraging preliminary safety and efficacy data for BBO-8520, BBO-11818 (including a partial response in pancreatic cancer), and BBO-10203. BBOT also extended its cash runway into 2028 and made key management appointments, including Pedro J. Beltran as CEO.
Key Highlights
- Cash, cash equivalents, and marketable securities totaled $388.9 million as of March 31, 2026.
- Cash runway is expected to fund operations into 2028.
- R&D expenses increased to $39.8 million in Q1 2026 from $20.6 million in Q1 2025.
- G&A expenses rose to $6.4 million in Q1 2026 from $2.5 million in Q1 2025.
- Net loss was $42.1 million for Q1 2026, compared to $22.1 million for Q1 2025.
- BBO-8520 showed 65% objective response rate (ORR) and 68% 6-month progression-free survival (PFS) in KRASG12C NSCLC.
- BBO-11818 demonstrated a partial response with 56% tumor reduction in a pancreatic cancer patient.
- Pedro J. Beltran, PhD, was appointed CEO, and Idan Elmelech as COO, effective April 20, 2026.